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To determine the evolution and trends of amoxicillin–
clavulanic acid resistance among Escherichia coli isolates 
in Spain, we tested 9,090 blood isolates from 42 Spanish 
hospitals and compared resistance with trends in outpatient 
consumption. These isolates were collected by Spanish 
hospitals that participated in the European Antimicrobial 
Resistance Surveillance System network from April 2003 
through December 2006. 
I
n addition to being an essential component of the gut 
ﬂ  ora, Escherichia coli is an etiologic agent for both hos-
pital- and community-acquired infections in humans (1–3). 
As with other bacterial pathogens, this bacterium can de-
velop resistance and multidrug resistance to several anti-
microbial families; consequently, antimicrobial treatment 
of invasive E. coli infections can be challenging (1).  
Amoxicillin–clavulanic acid (AMC) is one of the most 
consumed antimicrobial agents in many countries (4–6), 
principally for respiratory and urinary tract infections. 
However, little is known about its impact on antimicrobial 
drug resistance, particularly in E. coli. E. coli is one of the 
indicator organisms of the European Antimicrobial Resis-
tance Surveillance System (EARSS) (7), an international 
network of surveillance systems that attempt to collect reli-
able and comparable antimicrobial resistance data on inva-
sive pathogens (1). 
The Study
The 42 participating Spanish hospitals were selected 
according to EARSS criteria (1,7). The total catchment 
population was ≈9 million people, or ≈22.5% of the Span-
ish population. The ﬁ  rst blood E. coli isolates obtained from 
each patient between 2003 and 2006 were included. Each 
laboratory identiﬁ  ed the strains and tested their suscepti-
bilities according to standard microbiologic procedures; 
all used commercial microdilution systems. Susceptibil-
ity data were interpreted according to Clinical Laboratory 
Standards Institute criteria (8). For epidemiologic purpos-
es, intermediate susceptibility to AMC was considered as 
resistance. Multidrug resistance was deﬁ  ned as resistance 
to >3 of the following antimicrobial agents: ciproﬂ  oxa-
cin, gentamicin, cotrimoxazole, and cefotaxime. To assess 
the comparability of susceptibility test results, an external 
quality assurance exercise (UK National External Quality 
Assessment Scheme) was performed yearly.
Hospital-acquired infections were deﬁ   ned as infec-
tions acquired at least 48 hours after hospital admission. 
Community-acquired infections were those in which E. 
coli–positive cultures were identiﬁ  ed at or within 48 hours 
of hospital admission. 
Outpatient consumption of penicillin/β-lactamase in-
hibitors (World Health Organization code J01CR02) for the 
period 2002–2006 was assessed from the Especialidades 
Consumo de Medicamentos database, which showed retail 
pharmacy sales of all medicines acquired with National 
Health System prescriptions and covered nearly 100% of 
the Spanish population (5). The information was tabulated, 
and the number of units was converted into deﬁ  ned daily 
doses (DDD) of active drug ingredients according to WHO 
methodology (9). The number of DDD per 1,000 inhabit-
ants per day (DIDs) was calculated for each active drug 
ingredient.  
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DOI: 10.3201/eid1408.071059Differences in the antimicrobial resistance prevalence 
between different groups were assessed by Fisher exact 
test. Association was determined by calculation of the odds 
ratio (OR) with 95% conﬁ  dence intervals (CI). The signiﬁ  -
cance of the antimicrobial resistance trends was calculated 
by χ2 test for trend. The null hypothesis was rejected for 
values of p<0.05. Statistical analyses were performed by 
using GraphPad Prism version 3.02 software (GraphPad 
Software, Inc., San Diego, CA, USA).  
Participating hospitals reported data on 9,090 cases 
of E. coli bacteremia during the study period, correspond-
ing to the same number of patients; 4,526 (49.8%) were 
male patients and 4,564 (50.2%) were female patients. A 
total of 1,531 cases (16.8%) were diagnosed in 2003; 2,526 
(27.8%) in 2004; 2,438 (26.8%) in 2005; and 2,597 (28.6%) 
in 2006. Of the total number of isolates, 328 (3.6%) were 
obtained from children <14 years of age; 2,857 (31.4%) 
were obtained from patients >15 and <64 years of age; and 
5,909 (65%) were obtained from patients >64 years of age. 
There were 3,384 (37.9%) isolates implicated in hospital-
acquired infections and 5,540 (62.1%) in community-ac-
quired infections; information was missing for 166 cases. 
Of the 9,090 E. coli isolates tested, 1,136 (12.5%) were 
nonsusceptible to AMC, 5.1% were resistant, and 7.4% 
were intermediate. The prevalence of amoxicillin/clavu-
lanic acid nonsusceptibility in relation to gender, age, in-
fection origin, and resistance to other antibimicrobial drugs 
is detailed in the Table.
Multidrug resistance was present in 198 (17.4%) of 
the nonsusceptible AMC isolates. The most prevalent phe-
notypes included multidrug resistance to ciproﬂ  oxacin, 
cotrimoxazole, and gentamicin, which was detected in 73 
nonsusceptible AMC isolates (36.9% of multiresistant iso-
lates and 6.4% of isolates overall), and resistance to cip-
roﬂ  oxacin, cotrimoxazole, and cefotaxime was detected in 
55 isolates (27.8% of multiresistant isolates; 4.9% of iso-
lates overall). Multidrug resistance was more prevalent in 
nosocomial (23.5%) than in community-acquired isolates 
(15.1%; OR 1.99, 95% CI 1.46–2.72; p<0.0001).
Among nonsusceptible AMC isolates, susceptibility 
to other antimicrobial drugs, including ciproﬂ  oxacin, gen-
tamicin, cefotaxime, and cotrimoxazole, was more frequent 
in community- (28.7%) than in hospital-acquired isolates 
(13.3%; OR 1.68, 95% CI 1.27–2.22; p = 0.0003). This 
suggests that more therapeutic options were available for 
community-acquired isolates. 
The overall rate of invasive E. coli nonsusceptibility to 
AMC increased from 9.3% (2003) to 15.4% (2006) (χ2 test 
for trend 36.51; p<0.0001) (Figure 1); this increase was ob-
served in 64.3% of the participant hospitals. This increase 
was also detected in both intermediate and resistant iso-
lates, with annual distributions of 5.6% and 3.8%, respec-
tively, in 2003; 6.8% and 4.8% in 2004; 7.5% and 5.4% in 
2005; and 9.4% and 6% in 2006. 
AMC nonsusceptibility according to age groups in-
creased over the study period as follows: children <14 years 
of age (10.6% in 2003, 14.6% in 2004, 14.3% in 2005, and 
16.3% in 2006); patients >15 and <64 years 9.6% in 2003, 
11.2% in 2004, 11.7% in 2005, and 13.3% in 2006); pa-
tients >64 years (8.8% in 2002, 11.3% in 2004, 15.9% in 
2005, and 16.3% in 2006). The prevalence of AMC non-
susceptibility in community-acquired infections increased 
from 8.9% (2003) to 15.6% (2006) (χ2 test for trend 29.43; 
p<0.0001). AMC nonsusceptibility in nosocomial infec-
tions increased from 9.2% (2003) to 15.2% (2006) (χ2 test 
for trend  11.94; p = 0.0006). 
In the ﬁ  nal 2 years of the study period (2005–2006), the 
proportion of AMC-nonsusceptible isolates increased from 
12.9% to 15.9%. This increase was due to community-ac-
quired E. coli isolates only; the nonsusceptible proportion 
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Table. Association of AMC nonsusceptibility of Escherichia coli from blood with gender, age, infection origin, and resistance to other 
antimicrobial agents, Spain, 2003–2006* 
Variable  AMC nonsusceptibility, %  Odds ratio  95% Confidence interval  p value 
Gender        
    Male  13.6 
    Female  11.4 
1.23  1.08–1.39  0.001 
Age        
    <14 y   14.2 
    >14 y  12.8 
1.12  0.83–1.52  0.51 
Infection origin         
    Nosocomial  13.8 
    Community  12.0 
1.18  1.04–1.34  0.012 
Antimicrobial susceptibility      
    Ciprofloxacin susceptible  9.0 
    Ciprofloxacin resistant  22.5 
2.93  2.59–3.32  <0.0001 
    Gentamicin susceptible  11.5 
    Gentamicin resistant  25.6 
2.64  2.22–3.14  <0.0001 
    ESBL-negative  11.5 
    ESBL-positive  30.7 
3.40  2.84–4.08  <0.0001 
*AMC, amoxicillin–clavulanic acid; ESBL, extended-spectrum ȕ-lactamase. Amoxicillin–Clavulanic Acid Resistance in E. coli
varied from 11.5% (2005) to 15.6% (2006) (OR 1.42, 95% 
CI 1.16–1.74; p = 0.0009) in community-acquired isolates 
compared with 15.4% (2005) to 15.2% (2006) in hospital-
acquired isolates (Figure 1). Community-acquired infec-
tion probably included healthcare-associated infections, a 
recently described epidemiologic category distinct from 
both community-acquired and nosocomial status.
In this study, the number of blood isolates of E. coli 
producing extended-spectrum β-lactamase (ESBL) was 614 
(6.7%); 188 of them (30.6%) were nonsusceptible to AMC. 
When ESBL-producing E. coli isolates were excluded from 
analysis, AMC nonsusceptibility increased from 8.4% 
(2003) to 14.3% (2006) (χ2 test for trend 34.39; p<0.0001) 
in total isolates; from 8.2% (2003) to 14.5% (2006) (χ2 test 
or trend 25.23; p<0.0001) in community-acquired isolates; 
and from 8.9% (2003) to 13.3% (2006) (χ2 test for trend 
6.35; p = 0.012) in hospital-acquired isolates (Figure 1).   
The proportion of isolates highly susceptible to AMC (MIC 
<4 mg/L) steadily decreased over the study period as fol-
lows: 70.2% (2003), 70% (2004), 64.8% (2005), and 57.4% 
(2006) (χ2 test for trend 99.36; p<0.0001).
Community consumption of penicillin/β-lactamase 
inhibitors, predominantly AMC, increased 34.7% from 
2000 to 2006 (Figure 2), whereas total antimicrobial drug 
consumption remained relatively constant (19.6 DIDs in 
2000 compared with 19.1 DIDs in 2006). After AMC, the 
most used β-lactam antimicrobial agents in the community 
in Spain were amoxicillin, cefuroxime, and ceﬁ  xime; their 
consumption did not vary or slightly decreased from 2002 
through 2005 (6).
Conclusions
The increased AMC resistance of E. coli isolates from 
blood observed in this study is of serious concern from 
clinical and epidemiologic standpoints because AMC is the 
ﬁ  rst-choice antimicrobial treatment for many invasive E. 
coli infections. Increased AMC resistance coincided with 
growing AMC consumption at the community level. In uri-
nary infections, previous treatment with AMC is a risk fac-
tor for the development of AMC resistance (10). AMC re-
sistance mechanisms (β-lactamase overproduction, AmpC 
cephalosporinase hyperproduction, and inhibitor-resistant 
penicillinases) (11) might be favored by strong AMC 
consumption.
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